EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Utility of glucagon-like-peptide-1-receptor agonists in mast cell activation syndrome

Lawrence B Afrin, Leonard B Weinstock, Tania T Dempsey, Katja Aschenbrenner, Svetlana Blitshteyn, Jill R Schofield

The American Journal of the Medical Sciences · 2025

DOI: 10.1016/j.amjms.2025.07.006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The American Journal of the Medical Sciences, 2025. Verfasst von Lawrence B Afrin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Mast Cell Studies, AIM Center for Personalized Medicine, Purchase, NY, USA. Electronic address: drafrin@aimcenterpm.com. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Mast Cells, Mastocytosis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Mast cell (MC) activation syndrome (MCAS) is a collection of illnesses rooted in inappropriate MC activation with little to no neoplastic MC proliferation, distinguishing it from mastocytosis. Due to great heterogeneity in the underlying MC regulatory gene mutational profiles present in most cases and resulting great heterogeneity in aberrant expression of the hundreds of potent mediators known to be expressed by MCs, MCAS presents with great heterogeneity but dominantly manifests as chronic multisystem polymorbidity of generally inflammatory, allergic, and dystrophic phenotypes. MCAS's heterogeneity at multiple levels poses challenges for identifying optimal individual treatment. Targeting commonly affected downstream effectors of the disease's various symptoms may yield clinical benefit independent of the root/upstream mutational profile in the individual patient. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) engage with GLP-1 receptors present on many types of cells, including MCs. These drugs are already approved for management of a few chronic inflammatory diseases (e.g., diabetes mellitus type 2, obesity, obstructive sleep apnea) but are increasingly being appreciated to help in a wide range of other inflammatory diseases. METHODS: We present the first case series showing utility of a variety of GLP-1RAs for managing refractory MCAS in a diverse assortment of such patients. RESULTS: Among 47 cases (mean age 39, range 15-71, 89 % female), 89 % demonstrated clinical benefit with GLP-1RAs for a broad range of problems associated with MCAS. CONCLUSION: GLP-1RAs may have substantial benefit in MCAS. Randomized controlled trials are needed to assess the efficacy, and identify optimal dosing, of GLP-1RA treatment in MCAS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsMast CellsMastocytosisAdultAgedFemaleHumansMaleMiddle AgedAdolescentYoung Adult

Stichwörter der Autor:innen

Chronic inflammatory diseasesGLP-1 agonistsGlucagon-like peptide-1 receptor agonistsMast cell activation diseaseMast cell activation syndrome

Substanzen

Glucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Department of Mast Cell Studies, AIM Center for Personalized Medicine, Purchase, NY, USA. Electronic address: drafrin@aimcenterpm.com.
  • Specialists in Gastroenterology, St. Louis, MO, USA.
  • Department of Integrative Medicine, AIM Center for Personalized Medicine, Purchase, NY, USA.
  • Department of Integrative Medicine, Arztpraxis Aschenbrenner, Berlin, Germany.
  • Department of Neurology, University of Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, USA.
  • Department of Internal Medicine, University of Colorado Anschutz School of Medicine, Aurora, CO, USA.

Zitieren

APA

Afrin, L. B., Weinstock, L. B., Dempsey, T. T., Aschenbrenner, K., Blitshteyn, S., & Schofield, J. R. (2025). Utility of glucagon-like-peptide-1-receptor agonists in mast cell activation syndrome. The American Journal of the Medical Sciences. https://doi.org/10.1016/j.amjms.2025.07.006

Vancouver

Afrin LB, Weinstock LB, Dempsey TT, Aschenbrenner K, Blitshteyn S, Schofield JR. Utility of glucagon-like-peptide-1-receptor agonists in mast cell activation syndrome. The American Journal of the Medical Sciences. 2025. doi:10.1016/j.amjms.2025.07.006

BibTeX
@article{Afrin2025,
  author = {Afrin, Lawrence B and Weinstock, Leonard B and Dempsey, Tania T and Aschenbrenner, Katja and Blitshteyn, Svetlana and Schofield, Jill R},
  title = {Utility of glucagon-like-peptide-1-receptor agonists in mast cell activation syndrome},
  journal = {The American Journal of the Medical Sciences},
  year = {2025},
  doi = {10.1016/j.amjms.2025.07.006}
}
Kostenlos starten →